Longitudinal SV2A and MRI in Premanifest HD
Recruiting
This study will compare the sensitivity of PET of synaptic vesicle(small, membrane-bound spheres found within nerve terminals of neurons ) protein 2A (SV2A) using a radioligand and volumetric MRI to detect brain longitudinal striatal changes in premanifest HD.
All subjects will undergo a clinical examination, with detailed assessment of motor and non-motor symptoms. This will include imaging evaluation using PET of SV2A using the radioligand 18F-SynVesT-1. And MRI of brain volume at baseline(initial visit) and 2 years
This an open label study with no phase assigned(not applicable). The intervention being the use of PET radioligands.
Ages Eligible
for Study:
20 Years to 75 Years
(Adult, Older Adult )
Sexes Eligible
for Study:
All
Accepts Healthy Volunteers:
Yes
- Capacity to understand the informed consent form.
- HD mutation carriers:
- HTT (CAG)n ≥ 40
- HD-ISS < 2
- CAP100 score > 70
- neuropsychiatric diseases (other than HD for HD mutation carriers)
- major internal medical diseases
- white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
- history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
- contraindications for MR
- pregnancy
- previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
LOCATION
BELGIUM
TRIAL SITE:
Universitaire Ziekenhuizen KU Leuven
Address: Leuven, Belgium
CONTACT: Wim Vandenberghe, MD, PhD
Email:wim.vandenberghe@kuleuven.be
